Two Systems, One Fight: How the Patent “Dance” and Orange Book Linkage Shape the $400B Biologics War
Biologics are supposed to be the future of medicine—precision therapies built on living systems. But the real battleground isn’t only in labs. It’s in …

Most teams don’t lose to competitors because they’re slower—they lose because they’re blind.
In pharma, timing isn’t a “nice to have.” It’s the difference between launching first and watching your opportunity get quietly engineered away.
Here’s the unc…

The patent cliff isn’t the endgame. It’s the opening move.
Most people think the moment a drug’s patent expires is when the market “turns over.” In reality, the real contest often begins before the cliff—when brand companies and generic challengers sta…

AI is your drug’s new KOL—and you’re not tracking it.
For years, pharma has built its influence map around a familiar cast: key opinion leaders, conference circuits, advisory boards, and the occasional “can’t-miss” publication. But the center of gravit…

Most companies don’t miss the patent—they miss the money.
Drug patent expiry is treated like a cliff. But in practice, it’s more like a slow leak: value starts draining long before the legal date hits. The companies that win aren’t the ones who wait fo…

Drug patent expiry isn’t a calendar event—it’s a portfolio risk model. Here’s how to forecast it by country.
Most pharma and biotech teams treat patent expiry like a single date on a single spreadsheet. In reality, it’s a moving target shaped by jurisd…

Generic entry is the moment the market stops forgiving. Prices compress, margins evaporate, and the “brand premium” that once felt durable suddenly looks fragile. Investors often focus on the obvious shields—compound patents, exclusivity periods, and b…

Biotech IPOs can feel like a clean bet: a compelling pipeline, a credible management team, and a market that’s hungry for the next breakthrough. But in biotech, the fastest way to get burned isn’t a failed trial—it’s a weak patent position you didn’t d…

Biosimilar entry windows are where strategy meets math—and where small modeling errors can turn into big financial misses.
In the biosimilar market, timing isn’t a footnote. It’s the difference between capturing early share and watching competitors l…

Generic & biosimilar development is a high-stakes game of timing, not just science.
Before you file—before you spend another dollar on formulation work, clinical planning, or manufacturing scale-up—there’s a question that can make or break your g…